Browse the corpus

Table of Contents Issues in Oncology TG@HRTUNC IN aes Such Zara oR SW Bs SOS 5 Bad FS or 8 SE, SD 17 Metastatic Disease: « sa.s2e 2:62 sases etme ie eews 18 TMtrOdUCHON: sa sede mes wesw tals erst meget oes sae w 1 Staging 6... cece eee eee 1 Dial CANCE »xm.s ayn mes eras wm Eom EwsemEE ERE TEE 19 Performance Status: a... 03 isms ese os e2 mas memes 1 PaTTCKEATIG CATIGCED « . xo ava Vale bce Senn sw on i 6 Bad's Sew cei Gini» 19 Goals Of Thetapy « esszi22nesmrses wesw rede ees ween 2 Gastroesophageal Cancer .siiciscicrswsssaveamemes 20 Understanding Cancer Terminology................. 3 Gastric Lymphoma «sacisssmswesmesmeweimesmimes 20 Treatment Approaches ............. 0.0 eee eee eee 3 Neuroendocriné TUMOSS «2 csavacsciwmsmeanewes wus 21 Traditional Cancer Therapies................... 4 Gastrointestinal Stromal Tumors................... 21 Precision Medicine «os. e.0eac2s+ssiaseeeaarsess 4 Immunotherapy ¢sisssediees wiseseseme mes mese 5 Lung Cancer Non-Small Cell Lung Gancer’. i 2s ssciasswiaaswiawes 22 Breast Cancer Barly=Stage DISGase : nes mssms weswaeme wes weemes 22 Introductions « <s.22 mes ena eames ns we Se seem Ew TEs 5 Locally Advanced Disease.................005. 22 Epidemiology and Risk Factors .................000- 5 Metastatic Disease..............2ssacass Seas reas 23

Introductions « <s.22 mes ena eames ns we Se seem Ew TEs 5 Locally Advanced Disease.................005. 22 Epidemiology and Risk Factors .................000- 5 Metastatic Disease..............2ssacass Seas reas 23 Chemoprevention and Other Risk Reduction Strategies . . 5 Small Gell Lung Cancer s2sse:eescismswerwesws wees 24 Staging and Prognosis of Early-Stage Breast Cancer... . 7 Primary Breast Cancer Therapy..................005 9 Head and Neck Cancer Ductal Carcinoma. i SIUM . 2 .s5 cscs ees wevesweems 9 Risk FactOrs ... 0... cece ee eee ees 25

Staging and Prognosis of Early-Stage Breast Cancer... . 7 Primary Breast Cancer Therapy..................005 9 Head and Neck Cancer Ductal Carcinoma. i SIUM . 2 .s5 cscs ees wevesweems 9 Risk FactOrs ... 0... cece ee eee ees 25 Invasive Breast Cancer .......... 0.00 c cee eens 9 Clinical Manifestations. .......... 2. ...06 cece eeneaess 25 Adjuvant Systemic Therapy for Nonmetastatic Evaluation and Staging ::=.6:sssseiweswiamewaswesy 25 Breast GanCery: =inegisism ite: eis witiecmesa i war eees 10 Treatment. ... 0... eee ene eee 25 Adjuvant Endocrine Therapy.................. 10 Posttreatment Surveillance ...............-2-0200- 26 Adjuvant Chemotherapy. ..................05. 1 Management of Recurrent Head and Locally Advanced and Inflammatory Breast Cancer... 12 Ne@GK GatieGiir. » 22022 Ginga ebee sm bem sews wesw iam ee 26 Breast Cancer Follow-up and Survivorship .......... 12 Metastatic Breast Cancer ...... 0... cc cece ee eee 13 Genitourinary Cancer Prostate Cancer... .. eee eee eee ee eee ee 26 Ovarian Cancer Epidemiology and Risk Factors ................ 26 Epidemiology and Risk Factors..................4. 14 Diagnosis and Staging....................008. 26 Risk-Reduction Strategies and Screening............ 14 Treatments < sass semesaieiseimereipeemesees ss a7

Invasive Breast Cancer .......... 0.00 c cee eens 9 Clinical Manifestations. .......... 2. ...06 cece eeneaess 25 Adjuvant Systemic Therapy for Nonmetastatic Evaluation and Staging ::=.6:sssseiweswiamewaswesy 25 Breast GanCery: =inegisism ite: eis witiecmesa i war eees 10 Treatment. ... 0... eee ene eee 25 Adjuvant Endocrine Therapy.................. 10 Posttreatment Surveillance ...............-2-0200- 26 Adjuvant Chemotherapy. ..................05. 1 Management of Recurrent Head and Locally Advanced and Inflammatory Breast Cancer... 12 Ne@GK GatieGiir. » 22022 Ginga ebee sm bem sews wesw iam ee 26 Breast Cancer Follow-up and Survivorship .......... 12 Metastatic Breast Cancer ...... 0... cc cece ee eee 13 Genitourinary Cancer Prostate Cancer... .. eee eee eee ee eee ee 26 Ovarian Cancer Epidemiology and Risk Factors ................ 26 Epidemiology and Risk Factors..................4. 14 Diagnosis and Staging....................008. 26 Risk-Reduction Strategies and Screening............ 14 Treatments < sass semesaieiseimereipeemesees ss a7 DISGNOSIS! ; ods wxsms boom reuseem caw & Fe eT ES 14 Metastatic Prostate Cancer............ 0.00 ee 28 Treatment. ... 0... cc eee eens 14 Testicular Cancer... 1... 2... eee eee 29 Monitoring and Follow-up..............2......0-- 15 Renal. Cell Carcinoma. ..... . ... 20.2203 ses @ Peels EME Za? 30 Management of Recurrent Ovarian Cancer .......... 15 BIsdder Cane? 22-2 m2 hes eis dwas mee Pe eraiwiewees: 31

DISGNOSIS! ; ods wxsms boom reuseem caw & Fe eT ES 14 Metastatic Prostate Cancer............ 0.00 ee 28 Treatment. ... 0... cc eee eens 14 Testicular Cancer... 1... 2... eee eee 29 Monitoring and Follow-up..............2......0-- 15 Renal. Cell Carcinoma. ..... . ... 20.2203 ses @ Peels EME Za? 30 Management of Recurrent Ovarian Cancer .......... 15 BIsdder Cane? 22-2 m2 hes eis dwas mee Pe eraiwiewees: 31 Cervical Cancer Lymphoid Malignancies Epidemiology and Risk Factors.................005 15 Epidemiology and Risk Factors .................005 31 Diagnosis, Staging, and Treatment ................. 16 Evaluationzand Diagnosis: =: se: is%.nei ses meseiaes 32 Prognosis and Surveillance ................0000005 16 Classifications, Staging, and Prognosis of Malignant Lymphoma............. 0.0.0 e cee eee 32 Gastroenterological Malignancies Non-Hodgkin Lymphomas ...................+4-- 32 Colorectal:Ganter 22 ssessmsmssWis wie ss es eR ER Es REE 17 Indolent B-Cell Lymphomas .................. 33 Aggressive B-Cell Lymphomas................. 35 SUAGING: . ee cece soul CPR ESSSRERR mE MeawEs 17

T-Cell TyMphomas sasisis.cvwcswccccsncememsee Central Nervous System Emergencies........... 43 Lymphoblastic Lymphoma.................... Malignant Pleural and Pericardial Effusions ..... 43 Hodgkin Lymphoma..............0...0 cece eee Metabolic Urgencies and Emergencies.............. 44 Tumor Lysis Syndrome.................000005 44 Cancer of Unknown Primary Site Hypercalcemia of Malignancy ................. 44

T-Cell TyMphomas sasisis.cvwcswccccsncememsee Central Nervous System Emergencies........... 43 Lymphoblastic Lymphoma.................... Malignant Pleural and Pericardial Effusions ..... 43 Hodgkin Lymphoma..............0...0 cece eee Metabolic Urgencies and Emergencies.............. 44 Tumor Lysis Syndrome.................000005 44 Cancer of Unknown Primary Site Hypercalcemia of Malignancy ................. 44 Introduction. ........ 0... e cece eee Diagnosis and Evaluation..................0..0005 Effects of Cancer Therapy and Survivorship Favorable Prognostic Subgroups of Cancer of Effects of Cancer Therapy. .............000 eee ee eee 44 Unknown Primary Site................0002.00000. Hematologic Toxicity .......... 0.0... eee eee 44 Poorly Differentiated Cancer of Unknown Nausea and Vomiting ..................0.0005 45 PHIMALY Sit@r +m essa 50902 ow deen ewan smn dane Dermatologic EffectS.. 0.00 cece e ........cece ee 45 Isolated Regional Lymphadenopathy ........... Disorders of Pulmonary Function.............. 45 Peritoneal Carcinomatosis in Women........... Disorders of Genitourinary and Kidney Function. . 46 Nonfavorable Subgroups of Cancer of Neurologic TOXIGY «20: se: ecsmiwaswiswines wen 46 Unknown Primary Site................0..0000000, Toxicities Related to Immune Dysregulation..... 46

Introduction. ........ 0... e cece eee Diagnosis and Evaluation..................0..0005 Effects of Cancer Therapy and Survivorship Favorable Prognostic Subgroups of Cancer of Effects of Cancer Therapy. .............000 eee ee eee 44 Unknown Primary Site................0002.00000. Hematologic Toxicity .......... 0.0... eee eee 44 Poorly Differentiated Cancer of Unknown Nausea and Vomiting ..................0.0005 45 PHIMALY Sit@r +m essa 50902 ow deen ewan smn dane Dermatologic EffectS.. 0.00 cece e ........cece ee 45 Isolated Regional Lymphadenopathy ........... Disorders of Pulmonary Function.............. 45 Peritoneal Carcinomatosis in Women........... Disorders of Genitourinary and Kidney Function. . 46 Nonfavorable Subgroups of Cancer of Neurologic TOXIGY «20: se: ecsmiwaswiswines wen 46 Unknown Primary Site................0..0000000, Toxicities Related to Immune Dysregulation..... 46 Survivorship Issues.........00 cece ee 0.00.0. eee eee 46 Melanoma Late Effects of Cancer Therapy................. 46 Treatment of Melanoma...................0..000- Survivorship Care Plan...............00000008 47 FOUOWAUDs a vases eros 25 ach 3 ib oe ences e dm see mom eens

Survivorship Issues.........00 cece ee 0.00.0. eee eee 46 Melanoma Late Effects of Cancer Therapy................. 46 Treatment of Melanoma...................0..000- Survivorship Care Plan...............00000008 47 FOUOWAUDs a vases eros 25 ach 3 ib oe ences e dm see mom eens Bibliography ...........................00.000. 47 Oncologic Urgencies and Emergencies Structural Urgencies and Emergencies.............. Self-Assessment Test....................000.000. 51 Superior Vena Cava Syndrome................. Venous Thromboembolism ................00. NGI casi teens Fain 69H 18S 6k vem end im cam nem 105